Otolaryngologists often are involved in clinical trials, and nearly all of us read publications based on pharmaceutical research . However, many physicians who are not involved routinely in drug development may be unfamiliar with the stages in the drug development process, and with related terminology. Understanding such information helps interpret literature.
Briefly, there are several stages in the drug development process. The first stages are preclinical. Once an idea has been put forth for a new product (the creation of new product concepts will not be addressed in this editorial), the investigator and/or sponsor initiates research by testing the new product in vitro. In vitro studies are followed by animal studies designed to provide information about toxic effects and the pharmacologic nature and behavior of the investigational drug. Following successful preclinical research, clinical research may be initiated.
The first step in clinical research is to apply to the u.s. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application. This is a complex application. Before issuing an IND number, the FDA reviews all preclinical research data, scientific information on the formulation of the investigational drug, manufacturing procedures and expertise, the qualifications of the proposed investigator, and the proposed clinical protocol. An IND is required not only for investigational drugs proposed by pharmaceutical companies or other private entities, but even for those proposed by federal agencies or the National Institutes of Health (NIH) intramural programs, prior to human use.
Phase I trials involve a small number of subjects, usually between 10 and 100.
These trials may include patients or normal volunteers. If the drug involves substantial risk or is likely to cause harm (such as immunosuppressive therapy or cytotoxic chemotherapy), it is appropriate to use patients, so long as they are fully informed and give their consent. Typically, unless the drug is targeted specifically for women's health concerns, Phase I trials seek normal male volunteers to assess the investigational drug's initial exposure to an entire population. Phase I trials reveal information about pharmacologic action, metabolism, and toxicity in humans and help create a preliminary, dose-related profile of side effects.
Phase II trials are tightly controlled studies with strict inclusion and exclusion criteria. They include a larger but still a relatively small number of subjects, not exceeding several hundred. Phase II trials evaluate the effectiveness of the drug in treating a particular condition in patients, and they provide further information about short-term side effects and risks.
Phase III trials may include thousands of patients. Generally, they are designed for rapid recruitment of subjects and are approved only after data from Phase II trials indicate that the drug is effective for the condition under study. Phase III trials provide greater insight into safety and efficacy, as well as risks, effects, and side effects. The risks/benefits information developed from Phase III trials affect FDA-approved labeling of the drug when it is brought to market.
An investigational drug can be brought to market if Phase III studies indicate adequate safety and efficacy. In order to obtain permission to market a new pharmaceutical product, a New Drug Application (NDA) is required. This is also a complex and exhaustive application that includes all clinical data, all safety data from clinical studies, drug formulation and manufacturing information, and the device." Otolaryngologists should be aware th at such regu lations exist an d may infl ue nce greatly th e viability of creative new dev ice concepts (in cludi ng surgical in strum ents and, particu larly, im plan ts) because th e costs assoc iated with federal approval can be p rohibitive. Physic ians interested in more informatio n on device development can probably obtain it m ost easily through their institutional review boards.
Drug (and device) development is complex, an d it is reg ulated strictly to ensure public safety. Requirements affect th e timing of development, product availability, product cost, and other factors. Since otolaryngologist s evaluate new products routinely on behalf of our patients, an d since we read so much literature arising from new product development and testing, it is important for us to be cognizant of the requirements and sta ges of product de velopment and to understand the various pha ses of the process. Such information is invaluable in interpreting the massive quanti ties of new information to which we are exposed dai ly. Phase IV trialsmay be conducted by a pharmaceutical company after a product is availa ble on the market and h as received FDA approval. Ph ase IV trials are pruden t an d inform ative, b ut they typ ically are not required by th e FDA. A company or investigator may choose to perform Phase IV studies to inves tigate the effects of different doses or dosing schedules from those used in Phase II and Phase III trials; to determine the behavior of the drug in different patient populations or in patients with earlier or more advanced stages of disease; to monitor long-term effecti ven ess of the new agent; to compare the drug with other drugs available on the market; or to compare the cost effectiven ess of the drug with that of other products.
There is an analogous, similarly rigorous process req uired for development of devices that has been required by the FDA since 1980. That process will not be disc ussed in detail in this editorial, b ut it is important to recog nize th at devices also m ust u n dergo clinical trials before they can be brought to m arket. The rigor and expense of the clinical trials p rocess varies depen din g up on whether the device is de term ine d to be a "significan t risk device" or "nons ign ificant risk
